Jagan Chilakamarri
Psychiatry · Suwanee, GANPI 1528000197
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,500 of the $24,966 with a category attached, or 74.1%. Supernus Pharmaceuticals, Inc. accounts for 81.0% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $20,214 and has fallen 93.0% since, to $1,407 in 2025. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $143.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$20K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$865
- AbbVie$736
- Johnson & Johnson$439
- Corium, LLC$411
- Tris Pharma Inc$377
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$18,50074%
- Travel & lodging$5022%
- Food & beverage$5,90424%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 61 | $20,225 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $865 |
| AbbVie(2 entities) | 29 | $736 |
| Johnson & Johnson | 5 | $439 |
| Corium, LLC | 4 | $411 |
| Tris Pharma Inc | 4 | $377 |
| Alkermes, Inc. | 3 | $364 |
| Axsome Therapeutics, Inc. | 10 | $323 |
| E.r. Squibb & Sons, L.L.C. | 2 | $230 |
| Teva Pharmaceuticals USA, Inc. | 1 | $128 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Eisai Inc. | 1 | $115 |
| Noven Pharmaceuticals, Inc. | 1 | $114 |
| Livanova USA, Inc. | 1 | $112 |
| Neurocrine Biosciences, Inc. | 1 | $111 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $62 |
| Lundbeck LLC | 1 | $62 |
| Ironshore Pharmaceuticals Inc. | 1 | $62 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Brainsway USA Inc | 2 | $33 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$19,338
- ARISTADA$1,456
- VRAYLAR$389
- Quillichew ER$366
- Quillivant$366
- Dyanavel XR$366
- ARISTADA INITIO$364
- Azstarys$269
- Auvelity$245
- INVEGA SUSTENNA$241
- COBENFY$230
- UZEDY$128
- CAPLYTA$125
- REXULTI$125
- Leqembi$115
- Xelstrym$114
- VNS Therapy Symmetry Model 8103 Generator$112
- SPRAVATO$112
- INGREZZA$111
- INVEGA TRINZA$106
How this compares
$24,966 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olanzapine | 14 | $854 |
| Risperidone | 15 | $84 |
| Trazodone Hcl | 15 | $82 |
| Clonazepam | 15 | $20 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Suwanee
- Richard PettyLoganville$2.9M
- Ann GrooverCalhoun$1.4M
- Todd AntinDecatur$1M
- Michael BanovMarietta$733K
- Ben HunterBrookhaven$499K
- Joel MorganValdosta$337K
- Munjal ShroffSmyrna$316K
- David PurselleAtlanta$307K
- Jose CangianoAthens$244K
- Michael BurkeAtlanta$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.